| atezolizumab based treatment |
| atezolizumab plus bevacizumab plus carboplatin plus paclitaxel |
| mNSCLC - L1 - all population 5 | |
| mNSCLC - L1 - EGFR mutant | |
| mNSCLC - L1 - PDL1 negative 1 | |
| mNSCLC - L1 - PDL1 positive 14 | |
| mNSCLC - L1 - TMB>10Mb 1 | |
| non squamous cell - mNSCLC - L1 | |
| non squamous - mNSCLC - L1 - all population 3 | |
| non squamous - mNSCLC - L1 - PDL1 positive | |
| non squamous - mNSCLC - L1 - Wild Type (WT) 6 | |
| squamous cell - mNSCLC - L1 | |
| squamous - mNSCLC - L1 - all population 4 | |
| squamous - mNSCLC - L1 - PDL1 positive | |
| squamous - mNSCLC - L1 - Wild Type (WT) | |